Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Washington
With
Gilead Sciences
GlaxoSmithKline
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
older than 18 years
HBsAg+ at screening and for at least 6 months prior to study entry
HBeAg+
HBV DNA greater than 6 log10 copies/mL
Platelet count greater than 50,000 platelets/mm3
Hemoglobin greater than 7.5 g/dL
ALT less than ULN
Estimated creatine clearance\>50 mL/min as estimated by the Crockcroft-Gault equation ((140-age) x (kg)/(serum creatine x 72) (for women x 0.85))
Female and male participants must be practicing an effective form of contraception (male or female condom with spermicide, diaphragm or cervical cap with spermicide, intrauterine device, hormonal contraception)
Serum alpha-fetoprotein less than 50 ng/mL within 30 days of study entry
Childs-Pugh score less than 7 and no ascites, variceal bleeding, or hepatic encephalopathy
able to give written informed consent and to comply with the study protocol
You may not be if
history or evidence of HIV, hepatitis C or hepatitis D
known or suspected hypersensitivity to adefovir or other nucleoside/nucleotide analogs.
history of clinically significant renal dysfunction
any active medical or psychiatric illness that, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance with the protocol
pregnancy or breastfeeding
receipt of systemic corticosteroids within 90 days of study entry
receipt of nephrotoxic drugs within 8 weeks prior to study screening or expected use of these agents during the course of the study
